Exelixis, Inc. (Nasdaq: EXEL) today announced that enrollment is complete for CONTACT-03, the global, phase 3 pivotal trial evaluating the efficacy an
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma
